CO6220856A2 - Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano - Google Patents
Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octanoInfo
- Publication number
- CO6220856A2 CO6220856A2 CO09089674A CO09089674A CO6220856A2 CO 6220856 A2 CO6220856 A2 CO 6220856A2 CO 09089674 A CO09089674 A CO 09089674A CO 09089674 A CO09089674 A CO 09089674A CO 6220856 A2 CO6220856 A2 CO 6220856A2
- Authority
- CO
- Colombia
- Prior art keywords
- crystalline
- salt form
- crystalline salt
- peaks
- forms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 12
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- -1 (S) -2,3-dihydroxy-propionyl Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 abstract 2
- 102000003840 Opioid Receptors Human genes 0.000 abstract 1
- 108090000137 Opioid Receptors Proteins 0.000 abstract 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90409007P | 2007-02-28 | 2007-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6220856A2 true CO6220856A2 (es) | 2010-11-19 |
Family
ID=39620376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09089674A CO6220856A2 (es) | 2007-02-28 | 2009-08-26 | Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US7943772B2 (https=) |
| EP (1) | EP2132204B1 (https=) |
| JP (2) | JP5512289B2 (https=) |
| KR (1) | KR101480530B1 (https=) |
| CN (1) | CN101616916B (https=) |
| AR (2) | AR065554A1 (https=) |
| AU (1) | AU2008219615B2 (https=) |
| BR (1) | BRPI0807974B8 (https=) |
| CA (1) | CA2678073C (https=) |
| CL (1) | CL2008000573A1 (https=) |
| CO (1) | CO6220856A2 (https=) |
| CY (1) | CY1115077T1 (https=) |
| DK (1) | DK2132204T3 (https=) |
| ES (1) | ES2402031T3 (https=) |
| HR (1) | HRP20130193T1 (https=) |
| IL (1) | IL200131A (https=) |
| MX (1) | MX2009009141A (https=) |
| MY (1) | MY148318A (https=) |
| NZ (1) | NZ578871A (https=) |
| PL (1) | PL2132204T3 (https=) |
| PT (1) | PT2132204E (https=) |
| RU (1) | RU2458061C2 (https=) |
| SI (1) | SI2132204T1 (https=) |
| TW (1) | TWI409067B (https=) |
| WO (1) | WO2008106159A1 (https=) |
| ZA (1) | ZA200905832B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY145633A (en) | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| TWI409067B (zh) | 2007-02-28 | 2013-09-21 | Theravance Inc | ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型 |
| TWI415850B (zh) * | 2007-07-20 | 2013-11-21 | Theravance Inc | 製備ｍｕ類鴉片受體拮抗劑之中間物的方法 |
| US7691878B2 (en) * | 2007-08-27 | 2010-04-06 | Theravance, Inc. | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| TWI423801B (zh) * | 2007-08-27 | 2014-01-21 | Theravance Inc | 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物 |
| US7947710B2 (en) * | 2007-08-27 | 2011-05-24 | Theravance, Inc. | Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| WO2009029252A1 (en) * | 2007-08-27 | 2009-03-05 | Theravance, Inc. | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| AU2010295464B2 (en) * | 2009-09-18 | 2015-11-26 | Merck Sharp & Dohme Corp. | Use of opioid receptor antagonist for gastrointestinal tract disorders |
| DK3277278T3 (da) | 2015-04-02 | 2020-04-06 | Theravance Biopharma R&D Ip Llc | Kombinationsdoseringsform af en my-opioid receptorantagonist og et opioid |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
| US6900228B1 (en) | 1998-03-10 | 2005-05-31 | Research Triangle Institute | Opiate compounds, methods of making and methods of use |
| GB9810671D0 (en) | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
| TWI244481B (en) | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| GB9912410D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
| US6467084B1 (en) * | 1999-12-16 | 2002-10-15 | Emware, Inc. | Systems and methods for reprogramming an embedded device with program code using relocatable program code |
| EP1263758A2 (en) | 2000-03-03 | 2002-12-11 | Ortho-McNeil Pharmaceutical, Inc. | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| US20020025948A1 (en) | 2000-06-23 | 2002-02-28 | Banks Bernard Joseph | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| EP1440059B1 (en) | 2001-10-22 | 2008-04-16 | Pfizer Products Inc. | 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists |
| US7381721B2 (en) | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| US20040204453A1 (en) | 2003-04-14 | 2004-10-14 | Pfizer Inc | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors |
| BRPI0409307A (pt) * | 2003-04-14 | 2006-04-25 | Pfizer Prod Inc | derivados de 3-azabiciclo[3.2.1]octano |
| US7056930B2 (en) | 2003-04-14 | 2006-06-06 | Pfizer Inc. | 2-Azabicyclo[3.3.1]nonane derivatives |
| CA2522199A1 (en) | 2003-04-15 | 2004-10-28 | Pfizer Products Inc. | 3-benzhydrylidene-8-aza-bicyclo¬3.2.1|octane derivatives with opioid receptor activity |
| US6992090B2 (en) | 2003-06-16 | 2006-01-31 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| EP1737853A1 (en) | 2004-02-03 | 2007-01-03 | Janssen Pharmaceutica N.V. | 3-(diheteroarylmethylene)-8-azabicyclo¬3.2.1|octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo¬3.2.1|octane derivatives |
| US7087749B2 (en) | 2004-03-11 | 2006-08-08 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| MY145633A (en) | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| JP2010509227A (ja) | 2006-11-07 | 2010-03-25 | ネクター セラピューティックス エイエル，コーポレイション | オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与 |
| TWI409067B (zh) | 2007-02-28 | 2013-09-21 | Theravance Inc | ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型 |
-
2008
- 2008-02-15 TW TW097105472A patent/TWI409067B/zh active
- 2008-02-25 CL CL200800573A patent/CL2008000573A1/es unknown
- 2008-02-27 RU RU2009135834/04A patent/RU2458061C2/ru active
- 2008-02-27 HR HRP20130193AT patent/HRP20130193T1/hr unknown
- 2008-02-27 MY MYPI20093401A patent/MY148318A/en unknown
- 2008-02-27 EP EP08726162A patent/EP2132204B1/en active Active
- 2008-02-27 US US12/072,534 patent/US7943772B2/en active Active
- 2008-02-27 CA CA2678073A patent/CA2678073C/en active Active
- 2008-02-27 KR KR1020097020094A patent/KR101480530B1/ko active Active
- 2008-02-27 DK DK08726162.4T patent/DK2132204T3/da active
- 2008-02-27 SI SI200830928T patent/SI2132204T1/sl unknown
- 2008-02-27 BR BRPI0807974A patent/BRPI0807974B8/pt not_active IP Right Cessation
- 2008-02-27 NZ NZ578871A patent/NZ578871A/en not_active IP Right Cessation
- 2008-02-27 PT PT87261624T patent/PT2132204E/pt unknown
- 2008-02-27 AU AU2008219615A patent/AU2008219615B2/en not_active Ceased
- 2008-02-27 PL PL08726162T patent/PL2132204T3/pl unknown
- 2008-02-27 WO PCT/US2008/002583 patent/WO2008106159A1/en not_active Ceased
- 2008-02-27 MX MX2009009141A patent/MX2009009141A/es active IP Right Grant
- 2008-02-27 ES ES08726162T patent/ES2402031T3/es active Active
- 2008-02-27 CN CN2008800059690A patent/CN101616916B/zh not_active Expired - Fee Related
- 2008-02-27 JP JP2009551709A patent/JP5512289B2/ja active Active
- 2008-02-28 AR ARP080100850A patent/AR065554A1/es not_active Application Discontinuation
-
2009
- 2009-07-29 IL IL200131A patent/IL200131A/en active IP Right Grant
- 2009-08-21 ZA ZA200905832A patent/ZA200905832B/xx unknown
- 2009-08-26 CO CO09089674A patent/CO6220856A2/es active IP Right Grant
-
2011
- 2011-04-06 US US13/081,162 patent/US8247555B2/en active Active
-
2012
- 2012-07-17 US US13/550,781 patent/US8536335B2/en active Active
-
2013
- 2013-04-08 CY CY20131100293T patent/CY1115077T1/el unknown
- 2013-05-10 JP JP2013099851A patent/JP2013151564A/ja not_active Withdrawn
- 2013-08-13 US US13/965,691 patent/US8816091B2/en active Active
-
2014
- 2014-07-16 US US14/333,003 patent/US9290491B2/en active Active
-
2016
- 2016-02-10 US US15/040,191 patent/US9949963B2/en active Active
-
2017
- 2017-07-31 AR ARP170102183A patent/AR109224A2/es unknown
-
2018
- 2018-03-13 US US15/919,678 patent/US10426766B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6220856A2 (es) | Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| PE20142353A1 (es) | Ansolvatos de sal de noribogaina | |
| CL2008002542A1 (es) | Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. | |
| ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
| AR110019A2 (es) | Forma cristalina de un compuesto de quinolinona-carboxamida | |
| BR112022010377A2 (pt) | Novos tiromiméticos | |
| UY28885A1 (es) | 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s) | |
| UY31069A1 (es) | Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones | |
| ECSP066730A (es) | Compuestos y procedimientos para uso | |
| ECSP10010346A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis | |
| UY31554A1 (es) | Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus | |
| NI201300072A (es) | Derivados de heteroarilo como moduladores nachr alfa 7 | |
| PE20071220A1 (es) | Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona y su proceso de preparacion | |
| UY31672A1 (es) | "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación" | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| BRPI0912267A2 (pt) | sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável. | |
| CR20190144A (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos | |
| AR100369A1 (es) | Composición de dosis fija de formoterol y budesonide | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| AR047922A1 (es) | Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos | |
| BRPI1011851A2 (pt) | Composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, epara tratar uma doença | |
| AR084882A1 (es) | Compuesto de 1-azabiciclo[2.2.2]octano y usos para el tratamiento de esquizofrenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |